Middle East Pharmaceutical Industries (4016.SR) Earnings Analysis
Middle East Pharmaceutical Industries (4016.SR) has no confirmed upcoming earnings date. Last quarter (2026-03-04) it beat with EPS 2.27 SAR vs 2.27 SAR est (0%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 20.17.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4016.SR next report earnings?
No confirmed upcoming earnings date is currently scheduled for 4016.SR. This page updates as the calendar is published.
4016.SR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-04 | 2.27 SAR | 2.27 SAR | 0% | Beat |
| 2025-08-10 | 0.709 SAR | n/a | n/a | n/a |
| 2025-05-12 | 0.554 SAR | n/a | n/a | n/a |
| 2025-02-18 | 1.28 SAR | n/a | n/a | n/a |
| 2024-11-07 | 0.1086 SAR | n/a | n/a | n/a |
| 2024-08-05 | 0.623 SAR | n/a | n/a | n/a |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
4016.SR valuation and analyst view
| Trailing P/E | 20.17 |
|---|---|
| Trailing EPS | 2.975 SAR |
| Price / book | 5.07 |
| Dividend yield | 2.30% |
| Market cap | 2.10B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Middle East Pharmaceutical Industries (4016.SR)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 4016.SR. This page updates as the calendar is published.
Did 4016.SR beat earnings last quarter?
In its 2026-03-04 report, 4016.SR posted EPS of 2.27 SAR versus a 2.27 SAR estimate — a beat of 0%.
What is 4016.SR's earnings track record?
Over the last 1 reported quarters with consensus data, 4016.SR beat estimates 1 times (100%).
What is 4016.SR's current P/E ratio and EPS?
4016.SR trades at a trailing P/E of 20.17 on trailing EPS of 2.974878035936666 SAR.
What do analysts rate 4016.SR?
4016.SR has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.